Literature DB >> 18180225

Breast cancers detected with imaging screening in the BRCA population: emphasis on MR imaging with histopathologic correlation.

Petrina A Causer1, Roberta A Jong, Ellen Warner, Kimberley Hill, John W Wong, Belinda N Curpen, Donald B Plewes.   

Abstract

The benefit of screening with breast magnetic resonance (MR) imaging for certain patient populations at high risk for breast cancer, most notably patients with a genetic mutation in the BRCA1 or BRCA2 gene, has been established in numerous studies and is now becoming part of routine clinical practice. Despite the lower sensitivity of mammography compared with that of MR imaging, the former remains the standard of care for screening any patient population. In the BRCA1 and BRCA2 populations, the inferior sensitivity and specificity of ultrasonography (US) limit its role as a screening tool, but US remains a vital diagnostic tool because of its ability to provide guidance for biopsy of many suspicious lesions detected with MR imaging. Important features of a screening program with breast MR imaging include the following: optimization of the MR imaging technique, an awareness of the imaging features of invasive and noninvasive breast cancers detected with MR imaging, an understanding of the limitations of the various imaging modalities in both the initial screening and subsequent diagnostic work-up evaluations, and the requirement for MR imaging-guided biopsy. Copyright RSNA, 2007.

Entities:  

Mesh:

Year:  2007        PMID: 18180225     DOI: 10.1148/rg.27si075503

Source DB:  PubMed          Journal:  Radiographics        ISSN: 0271-5333            Impact factor:   5.333


  6 in total

1.  Ultrasonographic characteristics and BI-RADS-US classification of BRCA1 mutation-associated breast cancer in Guangxi, China.

Authors:  Cheng Li; Junjie Liu; Sida Wang; Yuanyuan Chen; Zhigang Yuan; Jian Zeng; Zhixian Li
Journal:  Int J Clin Exp Med       Date:  2015-02-15

2.  Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.

Authors:  Julia Krammer; Katja Pinker-Domenig; Mark E Robson; Mithat Gönen; Blanca Bernard-Davila; Elizabeth A Morris; Debra A Mangino; Maxine S Jochelson
Journal:  Breast Cancer Res Treat       Date:  2017-03-25       Impact factor: 4.872

3.  Multimodality breast cancer screening in women with a familial or genetic predisposition.

Authors:  I Trop; L Lalonde; M H Mayrand; J David; N Larouche; D Provencher
Journal:  Curr Oncol       Date:  2010-06       Impact factor: 3.677

4.  Outcome of long term active surveillance for estrogen receptor-positive ductal carcinoma in situ.

Authors:  Anna F Meyerson; Juan N Lessing; Kaoru Itakura; Nola M Hylton; Dulcy E Wolverton; Bonnie N Joe; Laura J Esserman; E Shelley Hwang
Journal:  Breast       Date:  2011-08-16       Impact factor: 4.380

5.  Intravenous Line Phase-Wrap Artifact at Bilateral Axial 3-T Breast MRI: Identification, Analysis, and Solution.

Authors:  Einat Slonimsky; Yusef Azraq; John M Gomori; Susan Fisch; Tal Arazi Kleinman; Tamar Sella
Journal:  Radiol Imaging Cancer       Date:  2020-11-06

6.  Breast carcinomas: variations in sonoelastographic appearance.

Authors:  Eduardo de Faria Castro Fleury; Maria do Carmo Guedes Alcoforado Assunção-Queiros; Decio Roveda
Journal:  Breast Cancer (Dove Med Press)       Date:  2014-08-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.